MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

MyoKardia (MYOK) Prices 3.75M Share Common Offering at $49/ShMay 23, 2018 5:40 AM MyoKardia (MYOK) Announces Proposed 3.75M Share Common OfferingMay 21, 2018 4:02 PM MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic CardiomyopathyMay 21, 2018 7:30 AM